Insmed (INSM): ENCORE Phase 3 Success Expands MAC Lung Disease Opportunity and Underscores Arikayce Upside

In a report released today, Danielle Brill from Truist Financial maintained a Buy rating on Insmed, with a price target of $205.00.

Danielle Brill has given his Buy rating due to a combination of factors that highlight the strategic significance of the ENCORE trial outcome for Insmed. He views the statistically robust Phase 3 results in newly diagnosed MAC lung disease, including both symptom improvement and durable culture conversion, as sufficient to support full approval in refractory patients and an expanded label to encompass the broader MAC LD population.

Brill also notes that while prescriber and payer dynamics may limit immediate, widespread front-line use, the potential tenfold expansion of the eligible patient pool, together with any incremental acceleration in Arikayce’s sales, represents meaningful upside versus his current assumptions. The planned supplemental NDA filing in the U.S. and parallel submissions in Japan further reinforce the visibility and durability of the Arikayce franchise, supporting a favorable risk–reward profile that underpins his Buy recommendation on INSM shares.

Based on the recent corporate insider activity of 139 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of INSM in relation to earlier this year.